Answers are grounded in this paper and cite their sources.
After selling their last company, Prometheus Therapeutics, to Merck & Co., Mark McKenna and a few other former Prometheus executives have founded another precision medicine start-up, Mirador Therapeutics. Mirador is looking at patients' molecular profiles for markers of immunofibrotic diseases and then developing drugs for those targets. Already the startup has secured $400 million in venture capital. Arch Venture Partners led the fundraising; other investors include OrbiMed, Fidelity Investments, and Sanofi's venture arm.
No takes yet. Share an insight, caveat, or question.
Rowan Walrath (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: